Close Menu

NEW YORK (GenomeWeb) – Hong Kong-based startup Take2 Health said today that it has licensed intellectual property from Grail for the early detection of nasopharyngeal carcinoma. Chinese University of Hong Kong researchers Dennis Lo, Rossa Chiu, and Allen Chan founded Take2 and have entered into a definitive agreement with Grail for the exclusive worldwide rights to an IP portfolio for early detection of NPC.

Additional details of the licensing agreement were not disclosed.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sep
25
Sponsored by
HalioDx

CAR T-cell therapy is an innovative form of immunotherapy that is finding increasing use for the management of blood cancers. 

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.